Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer

Plain-language summary

This study examines how different BRCA1/2 gene variants affect treatment response and prognosis in ovarian cancer. It enrolls patients diagnosed with ovarian cancer and tested for BRCA by the end of 2021, who were followed for at least one year. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Intervention

Patients must have been diagnosed with ovarian cancer and be BRCA positive, BRCA1 and BRCA2 positive, and be affected by Ovarian Cancer

Start date

7/1/2022

Estimated completion

12/31/2025

Countries

Italy

Related genes

Locations

• Bologna, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* ovarian cancer diagnosis by 31/12/2021;
* BRCA test at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S.Orsola by 31/12/2021;
* follow-up and/or treatment at Medical Oncology and/or Gynaecological Oncology of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months

Exclusion Criteria:

* ovarian carcinoma of 'mucinous' or 'borderline' histotype.